The plant is crucial for the company, producing 25% of its global insulin output. The modernization efforts aim to enhance production capabilities and incorporate sustainability projects that align with global environmental goals.
Since its establishment in 2007, the Montes Claros facility has supplied insulin to Brazil’s national health system and has also served as an export hub for international markets.
The modernization of the plant is expected to create new jobs and boost the local economy while reinforcing Novo Nordisk’s position as a leader in the global insulin market.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.